This article is more than 5 years old. Information may no longer be current.

MediBeacon receives breakthrough device status for transdermal GFR measurement system

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MediBeacon Inc. announced it received a breakthrough device designation from the FDA for the company’s transdermal GFR measurement system, which is designed to provide continuous real-time measurement of GFR with no need for blood sampling or urine collection.

Designated to be a combination product by the FDA, the transdermal GFR measurement system includes an optical skin sensor, monitor and a proprietary fluorescent tracer agent that glows in the presence of light, according to a company press release.

“We are delighted that the FDA has recognized the transdermal GFR measurement system meets the requirements for this designation,” Steve Hanley, CEO of MediBeacon, said in the release. “We look forward to continued close collaboration with the FDA as we begin our pivotal multicenter clinical study in the United States and Europe.”

The release noted that tracer agents and devices from MediBeacon, including the transdermal GFR measurement system, are not approved or cleared for human use by any regulatory agency.

Reference:

www.medibeacon.com/news/1771/